Abstract
MicroRNAs have emerged as key players of gene regulation during development and disease states like cancer and cardiovascular diseases. Pulmonary arterial hypertension (PAH), a vascular disease characterized by pulmonary resistance and vessel occlusion, is not spared by microRNA implication. This is not surprising since PAH shares common aberrantly activated pathways with cancers that lead to proliferation and survival of pulmonary arterial smooth muscle cells, among others, within the artery wall and narrowing the lumen. Recent studies demonstrated the role of miR-204 and miR- 206 in pulmonary artery smooth muscle cell (PASMC) proliferation. Other microRNAs, such as miR-145, miR-21 and the miR17/92 cluster, have been associated with the disrupted BMPR2 pathway. During the last couple of years, the number of studies on the role of microRNA in PAH has broadened, defining it clearly as a HOT TOPIC. This current review presents an overview of the most recent knowledge as well as future possibilities. The use of microRNA therapies is still uncertain and poorly applied in the clinical setting yet. It is still critical to increase the knowledge and the translational potential of this HOT TOPIC to make it become a HOPE TOPIC.
Keywords: Biomarker, microRNA, molecular biology, pulmonary arterial hypertension, remodeling, therapeutic target.
Current Vascular Pharmacology
Title:Therapeutic Potential of microRNA Modulation in Pulmonary Arterial Hypertension
Volume: 13 Issue: 3
Author(s): Jolyane Meloche, Roxane Paulin, Steeve Provencher and Sebastien Bonnet
Affiliation:
Keywords: Biomarker, microRNA, molecular biology, pulmonary arterial hypertension, remodeling, therapeutic target.
Abstract: MicroRNAs have emerged as key players of gene regulation during development and disease states like cancer and cardiovascular diseases. Pulmonary arterial hypertension (PAH), a vascular disease characterized by pulmonary resistance and vessel occlusion, is not spared by microRNA implication. This is not surprising since PAH shares common aberrantly activated pathways with cancers that lead to proliferation and survival of pulmonary arterial smooth muscle cells, among others, within the artery wall and narrowing the lumen. Recent studies demonstrated the role of miR-204 and miR- 206 in pulmonary artery smooth muscle cell (PASMC) proliferation. Other microRNAs, such as miR-145, miR-21 and the miR17/92 cluster, have been associated with the disrupted BMPR2 pathway. During the last couple of years, the number of studies on the role of microRNA in PAH has broadened, defining it clearly as a HOT TOPIC. This current review presents an overview of the most recent knowledge as well as future possibilities. The use of microRNA therapies is still uncertain and poorly applied in the clinical setting yet. It is still critical to increase the knowledge and the translational potential of this HOT TOPIC to make it become a HOPE TOPIC.
Export Options
About this article
Cite this article as:
Meloche Jolyane, Paulin Roxane, Provencher Steeve and Bonnet Sebastien, Therapeutic Potential of microRNA Modulation in Pulmonary Arterial Hypertension, Current Vascular Pharmacology 2015; 13 (3) . https://dx.doi.org/10.2174/15701611113119990010
DOI https://dx.doi.org/10.2174/15701611113119990010 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Novel Strategy for Synthesis of Gold Nanoparticle Self Assemblies
Current Nanoscience Pharmacological Therapy in Children with Atrioventricular Reentry: Which Drug?
Current Pharmaceutical Design Role of Apoptosis in the Pathogenesis of Contrast Media-induced Nephropathy and Hints for its Possible Prevention by Drug Treatment
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Memantine Treatment in Patients with Mild to Moderate Alzheimers Disease Already Receiving a Cholinesterase Inhibitor: A Randomized, Double-Blind, Placebo-Controlled Trial
Current Alzheimer Research Large Artery Stiffness and Antihypertensive Agents
Current Pharmaceutical Design Cardiac and Renal Nitric Oxide in the Adaptation to Hypovolemic Shock
Current Enzyme Inhibition New Developments In Treatment After Lung Transplantation
Current Pharmaceutical Design Tobacco Smoking and Association between Betel Nut Chewing and Metabolic Abnormalities Among Military Males: The CHIEF Study
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial (Hot Topic: Proteolytic Inhibitors: Implications on Microorganisms Development, Virulence and Pathogenesis)
Current Medicinal Chemistry Molecular Targets of Diabetic Cardiovascular Complications
Current Drug Targets A Review on the Risk of Myocardial Infarction Associated with the NSAID Diclofenac
Cardiovascular & Hematological Disorders-Drug Targets Dipeptidyl-peptidase 4 Inhibition: Linking Metabolic Control to Cardiovascular Protection
Current Pharmaceutical Design Synthesis of Sildenafil Citrate and Process Related Impurities
Letters in Organic Chemistry Fractional Flow Reserve: Physiological Basis, Advantages and Limitations, and Potential Gender Differences
Current Cardiology Reviews The Concomitance of Hypertension and Diabetes Exacerbating Retinopathy: The Role of Inflammation and Oxidative Stress.
Current Clinical Pharmacology Microvascular Function/Dysfunction Downstream a Coronary Stenosis
Current Pharmaceutical Design Recent Applications of Benzimidazole as a Privileged Scaffold in Drug Discovery
Mini-Reviews in Medicinal Chemistry Interstitial Lung Disease in Idiopathic Inflammatory Myopathy
Current Rheumatology Reviews Hepatic Encephalopathy: Cause and Possible Management with Botanicals
Recent Patents on Inflammation & Allergy Drug Discovery Pulmonary Circulation and Pulmonary Function in Neonatal Lung Hypoplasia:Treatment with Corticosteroids
Current Pediatric Reviews